header logo image


Page 25«..1020..24252627..3040..»

Archive for the ‘Death by Stem Cells’ Category

Families of Boys with Duchenne Muscular Dystrophy Band Together to Fund Research – Newswise (press release)

Wednesday, April 12th, 2017

Newswise BALTIMORE, MD (April 12, 2017) Three grassroots foundations founded by the families of young boys diagnosed with Duchenne muscular dystrophy (DMD) have jointly awarded a $100,000 grant to Kennedy Krieger Institutes Center for Genetic Muscle Disorders for research into novel drug therapies. The funding from Ryans Quest, of New Jersey, along with Michaels Cause and Pietros Fight, both of New York, will enable the scientific team to study existing drugs that have shown early therapeutic promise in cell cultures.

"We remain dedicated to helping identify existing FDA-approved drugs that can be repurposed to help treat Duchenne muscular dystrophy and ultimately expedite potential therapies for patients," said David Schultz, co-founder of Ryans Quest and father of 11-year-old Ryan, who has DMD.

Researcher Dr. Kathryn Wagner, and her colleagues Gabsang Lee and Congshan Sun, recently screened existing drugs using human myoblasts derived from induced pluripotent stem cells (iPSCs) from individuals living with DMD. The iPSCs are a type of stem cell that can be generated from mature living cells. Several drugs reliably produced a positive therapeutic response in the cells in culture. With this funding, the findings will be validated and trialed in the mouse model for DMD. As many of these drugs are already FDA approved, researchers and families are hopeful that a promising discovery in the mouse model could rapidly translate to clinical trials.

We are so grateful to these families, who in addition to raising three wonderful boys, Ryan, Michael and Pietro, are also working hard with us to develop novel treatments to combat DMD, said Dr. Kathryn Wagner, Director of the Center for Genetic Muscle Disorders at Kennedy Krieger Institute. Our team is deeply inspired by the grassroots efforts of families across the country who are raising critical dollars to fund research.

About Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disorder that causes a loss of motor, pulmonary, and cardiac function, and premature death. It is one of the most common pediatric genetic disorders, affecting every 1 in 5,000 live male births and some females. DMD is caused by the body's inability to create dystrophin, a large protein found in muscle cells. Children with DMD usually lose their ability to walk around the age of 12 and succumb to the disease in their early to mid-twenties. There is no FDA approved treatment or cure.

Ryans Quest, Michaels Cause and Pietros Fight are non-profits founded by families of boys and young men with Duchenne muscular dystrophy who believe that their global collaboration is paramount to see potential therapies through the drug pipeline.

ABOUT THE KENNEDY KRIEGER INSTITUTE

Internationally recognized for improving the lives of children and adolescents with disorders and injuries of the brain, spinal cord and musculoskeletal system, the Kennedy Krieger Institute in Baltimore, MD, serves more than 20,000 individuals each year through inpatient and outpatient clinics, home and community services and school-based programs. Kennedy Krieger provides a wide range of services for children with developmental concerns mild to severe, and is home to a team of investigators who are contributing to the understanding of how disorders develop while pioneering new interventions and earlier diagnosis. For more information on the Kennedy Krieger Institute, visitwww.kennedykrieger.org.

# # #

See the article here:
Families of Boys with Duchenne Muscular Dystrophy Band Together to Fund Research - Newswise (press release)

Read More...

Stem cells offer hope for autism – fox6now.com

Wednesday, April 12th, 2017

fox6now.com
Stem cells offer hope for autism
fox6now.com
Even Duke researchers acknowledge as much. The initial trial, published Wednesday in the journal Stem Cells Translational Medicine, was a safety study, not a controlled, double-blind study with definitive proof of positive results. This study was open ...

and more »

Read more from the original source:
Stem cells offer hope for autism - fox6now.com

Read More...

Solid Advances in Tumor Microenvironment Research – Genetic Engineering & Biotechnology News

Monday, April 10th, 2017

Immune Cells Gone Wrong

In a talk provocatively titled MacrophagesEvildoers in Cancer, Jeffrey W. Pollard, Ph.D., of the MRC Centre for Reproductive Health at the University of Edinburgh, described how tumor evolution to malignancy requires manipulation of its tissue microenvironment. This is particularly true, he noted, for the immune infiltrate that is biased away from responding to the tumor to effect control and instead actively promotes progression.

The tumor immune response thus downregulates cytotoxic T-cell responses and promotes tissue repair and morphogenic activities of the infiltrating immune cells, Dr. Pollard indicated in his abstract. Thus, the environment tends to be dominated by innate immune cells, particularly macrophages and neutrophils, while cytotoxic T cells are often excluded.

Dr. Pollards group has been interested in macrophages. In many different mouse models of cancer, these immune cells have been shown to promote tumor progression and enhance metastasis. In fact, he emphasized, macrophages appear to be involved in every step of tumor progression. They stimulate tumor initiation, enhance angiogenesis, promote tumor cell migration and intravasation, increase stem cell viability, suppress immune responses, and, at the metastatic site, promote extravasation and persistent growth.

Macrophage ablation, Dr. Pollards team has observed, results in inhibition of tumor progression and metastasis. It has also found that macrophage biologic activities are induced through a dynamic interplay with tumor cells that often involves reciprocal signaling.

Dr. Pollards group has been particularly interested in the involvement of macrophages in enhancing metastasis, since it is metastatic disease that is responsible for most cancer deaths. The group, stated Dr. Pollard, has demonstrated a chemokine-signaling cascade that results in the recruitment of the progenitor monocytes and their retention in the tissue. This results, he continued, in differentiation of what we have termed metastasis-associated macrophages (MAMs).

MAMs confer survival signals and growth advantage to metastatic cells, elaborated Dr. Pollard. The MAMs, in turn, respond to local signals to upregulate an inflammatory gene signature through the tyrosine kinase transmembrane receptors, vascular endothelial growth factor receptor 1 (VEGFR1 or FLT1) and colony stimulating factor 1 receptor (CSF1R). Furthermore, monocytes appear to be preadapted by the primary tumor to promote metastasis by the generation of preferred sites known as premetastatic niches. Thus, understanding monocyte biology, the mechanisms of their recruitment, and differentiation is of central importance to the fundamental appreciation of the role of macrophages in the tumor.

Read more here:
Solid Advances in Tumor Microenvironment Research - Genetic Engineering & Biotechnology News

Read More...

Community pays tribute to Sharon Berger – Jewish Chronicle

Monday, April 10th, 2017

Sharon Berger, the grandmother who launched an international hunt for a bone-marrow donor after being diagnosed with leukaemia, leaves behind an inspirational legacy that will save lives, say her family.

Mrs Berger, 65, succumbed to her illness last week after a five-year battle that united the community behind her search for a donor.

She passed away surrounded by family in Hammersmith Hospital where she was being treated.

Her son Jonni Berger said her family were devastated but were taking strength from the huge number of people who have joined the stem cell register because of her campaign.

In December 2012 Mrs Berger fell seriously ill with myelodysplastic syndrome (MDS), a malfunction of the bone marrow in producing blood cells, and underwent intensive chemotherapy in hospital while waiting for a transplant.

A donor was found following a four-month campaign known by its Twitter hashtag #Spit4Mum.

Many celebrities pledged their support on social media, including singer Britney Spears, Israeli model Bar Refaeli, One Direction member Liam Payne, singer Olly Murs, and comedian Eddie Izzard.

After a routine blood test in July 2016, Mrs Berger received the devastating news that her cancer had returned and started several weeks of chemotherapy.

Her son said: It was a huge blow to the family. She had to have a second transplant and I was her donor but I was only a 50 per cent match.

Although it extended her life, it didnt cure the leukaemia.

He added: Tributes have poured in from around the world as well as from across the British Jewish community, including from the Reform, Liberal, United synagogue movements as well as from the communities of Stamford Hill. The Spit4Mum campaign brought people together to save lives irrespective of their affiliation or denomination.

Over 1,190 Jewish people joined the Anthony Nolan donor register in the first four weeks of the campaign and the number has grown significantly since.

Jewish areas in London now have the highest concentration of stem cells donors, as a result of the Spit4Mum campaign.

Henny Braund, Anthony Nolans chief executive, said: Sharon spoke eloquently about her experiences of MDS and leukaemia, as well as the challenges she faced with her transplant.

It was a privilege to know and work with her. She will be sorely missed by all at Anthony Nolan.

Mr Berger said: I think her death leaves an inspirational legacy that will hopefully save lives.

His mother, whose funeral at the Western cemetery in Cheshunt on Sunday was attended by hundreds of people, was lucid and communicating with her family right up to the end of her life.

Mr Berger said: She was proud of what she had done, and worried about her family and wanted to know that we would all be OK.

Before her death the grandmother-of-two who was from north-west London and belonged to Finchley Reform Synagogue was able to see her daughter Caroline get married in an intimate ceremony attended by immediate family.

Mr Berger said: That was important to her and Caroline. She was able to come out of hospital and see it happen.

Mrs Bergers daughter in law, Rabbi Miriam Berger, of Finchley Reform Synagogue said: As a community we are already seeing Sharons legacy live on.

It was only a few weeks ago that a member of the shul in her twenties, who registered through the Spit4Mum campaign, donated her stem cells as an anonymous donor. While it doesnt take away our sadness to have lost Sharon it does give us hope that others will have the gift of life.

Rabbi Avraham Pinter, a prominent figure in the strictly Orthodox community of Stamford Hill said Mrs Berger had a great zchus (merit) in getting so many people on to the bone marrow register.

Read the original:
Community pays tribute to Sharon Berger - Jewish Chronicle

Read More...

Mighty morphed brain cells cure Parkinson’s in mice, but human trials still far off – STAT

Monday, April 10th, 2017

M

ice that walk straight and fluidly dont usually make scientists exult, but these did: The lab rodents all had a mouse version of Parkinsons disease and only weeks before had barely been able to lurch and shuffle around their cages.

Using a trick from stem-cell science, researchers managed to restore the kind of brain cells whose death causes Parkinsons. And the mice walked almost normally.The same technique turned human brain cells, growing in a lab dish, into the dopamine-producing neurons that are AWOL in Parkinsons, scientists at Swedens Karolinska Institute reportedon Monday in Nature Biotechnology.

Success in lab mice and human cells is many difficult steps away from success in patients. The study nevertheless injected new life into a promising approach to Parkinsons that has suffered setback after setback replacing the dopamine neurons that are lost in the disease, crippling movement and eventually impairing mental function.

advertisement

This is not going to happen in five years or possibly even 10, but Im excited about the potential of this kind of cell replacement therapy, said James Beck, chief scientific officer of the Parkinsons Foundation, which was not involved in the study. It could really give life back to someone with Parkinsons disease.

There is no cure for Parkinsons, a neurodegenerative disease that affects an estimated 10 million people worldwide, most prominently actor Michael J. Fox. Drugs that enable the brain to make dopamine help only somewhat, often causing movement abnormalities called dyskinesia as well as bizarre side effects such as a compulsion to gamble; they do nothing to stop the neurodegeneration.

As Parkinsons patients wait, Fox Foundation and scientist feud over drug trial

Rather than replacing the missing dopamine, scientists led by Karolinskas Ernest Arenas tried to replace dopamine neurons but not in the way that researchers have been trying since the late 1980s. In that approach, scientists obtained tissue containing dopamine neurons from first-trimester aborted fetuses and implanted it intopatients brains.Although a 2001clinical trialfound that the transplants partly alleviated the rigidity and tremors of Parkinsons, the procedure caused serious dyskinesia in about 20 percent of patients, Beck said. More problematic is that fetal issue raises ethical concerns and is in short supply.

It was clear that usable fragments of brain tissue were extremely difficult to recover, said Dr. Curt Freed, of the University of Colorado, who pioneered that work.

Instead, several labs have therefore used stem cells to produce dopamine neurons in dishes. Transplanted into the brains of lab rats with Parkinsons, the neurons reduced rigidity, tremor, and other symptoms. Human studies are expected to begin in the US and Japan this year or next, Beck said.

In the Karolinska approach, there is no need to search for donor cells and no cell transplantation or [need for] immunosuppression to prevent rejection, Arenas told STAT. Instead, he and his team exploited one of the most startling recent discoveries in cell biology: that certain molecules can cause one kind of specialized cell, such as a skin cell, to pull a Benjamin Button, aging in reverse until they become like the embryonic cells called stem cells. Those can be induced to morph into any kind of cell heart, skin, muscle, and more in the body.

Muhammad Ali and Parkinsons disease: Was boxing to blame?

Arenas and his team filled harmless lentiviruses with a cocktail of four such molecules. Injected into the brains of mice with Parkinsons-like damage, the viruses infected plentifulbrain cells called astrocytes. (The brains support cells, astrocytes perform jobs like controlling blood flow.)The viruses also infected other kinds of cells, but their payload was designed to work only in astrocytes, and apparently caused no harm to the other cells.

The molecules, called transcription factors, reprogrammed some of the astrocytes to become dopamine neurons, which were first detected three weeks later in the mouse brains. The dopamine neurons were abundant 15 weeks later, an indication that after changing into dopamine neurons the astrocytes stayed changed.

Five weeks after receiving the injections, the mice, which used to have Parkinsons-like gait abnormalities, walked as well as healthy mice. That suggests that direct reprogramming [of brain cells] has the potential to become a novel therapeutic approach for Parkinsons, Arenas told STAT.

That could have value for preserving the brain circuitry destroyed by Parkinsons, said Colorados Freed.

A lot of hurdles need to be overcome before this becomes a Parkinsons treatment. The Trojan horse system for delivering the reprogramming molecules inside viruseswould need to turn more astrocytes into dopamine neurons and leave other kinds of cells alone: Although viruses getting into mouse brain cells apparently caused no harm, that might not be so in people. We will need to use virus with selective [attraction] for astrocytes, Arenas said.

The morphed cells would presumably be ravaged by whatever produced Parkinsons in the first place. But in other cell transplants, Arenas said, the disease catches up with transplanted cells in 15 to 20 years, buying patients a good period of time. He thinks it might be possible to give patients a single injection but hold off some of the reprogramming with a drug, turning it on when the brain again runs short of dopamine neurons.

The basic technology to develop such strategies currently exists, he said.

The Karolinska lab is working to make the techniquesafer and more effective, including by using viruses that would deliver reprogramming molecules only to astrocytes. We are open to collaborations aimed at human studies, Arenas said.

Would patients be willing to undergo brain injections? People with Parkinsons disease, Beck said, are willing to go through a lot for any hope of improvement.

Sharon Begley can be reached at sharon.begley@statnews.com Follow Sharon on Twitter @sxbegle

Read the original:
Mighty morphed brain cells cure Parkinson's in mice, but human trials still far off - STAT

Read More...

Mesoblast takes off as cell therapy for heart failure passes interim test – FierceBiotech

Monday, April 10th, 2017

At the halfway point, a phase 3 trial of Mesoblast's off-the-shelf cell therapy for chronic heart failure is on track and should continue to completion, say advisers.

Shares in the Australian biotech hit a 12-month high on the update from the trial, which came after it enrolled 270 out of a planned total of 600 patients with moderate CHF andcruciallyrevealed no safety issues with Mesoblast's MPC-150-IM candidate.

The trial is still blinded so there is now way to tell if the therapy is having an effect, but it's a case of so far, so good, as the biotech looks ahead to completing the study next year.

The trial is seeing whether delivery of mesenchymal precursor cells (MPCs) via a catheter into the left ventricular heart muscle, to see if it can reduce non-fatal heart failure-related major adverse cardiac events (HF-MACE), such as death, needing a pacemaker implanted or undergoing a heart transplant.

Last year, Israeli drugmaker Teva returned rights to MPC-150-IM to Mesoblast, which it had inherited through its takeover of Cephalon. Mesoblast however decided to go it alone, a decision helped by a recent $40 million placement intended to help bring the CHF trial to fruition.

Analyst John Savin at Edison said in a recent note that the biotech may not have to wait for its own trial to complete before filing for U.S. approval. That could happen before the end of the year if a National Institutes of Health-sponsored trial of the therapy in end-stage heart failure patients hits the target.

The 159-patient NIH study is expected to complete enrolment in the first half andwith luckcould report top-line data before year-end, according to Savin. He reckons that could "lead to an application for accelerated approval" under the U.S. 21st Century Cures Act, which provides a speedy route to market for regenerative medicines.

"Passing this interim futility analysis for MPC-150-IM is an important milestone for Mesoblast and our cardiovascular disease program," commented CEO Silviu Itescu. "This validates our strategy and our prioritization of this valuable program." Analysts at Credit Suisse have previously suggested that that drug could be worth $4.1 billion in peak annual sales.

Mesoblast is not the only biotech looking at a stem cell approach to cardiovascular diseases. BioCardia is developing CardiAMP for CHF, reporting positive data from small phase 2 trial last year, while CardioCell presented mixed results on its candidate at the 2016 ESC Congress in Rome, and Celyad's C-Cure product failed to meet its objectives in its phase 3 CHART trial. Meanwhile, Belgium's TiGenix said recently its acute myocardial infarction therapy AlloCSC-01 hit its targets in a phase 1/2 trial.

The Australian biotech claimed an FDA green light to start trials of an MPC therapy given alongside corrective heart surgery for children with hypoplastic left heart syndrome (HLHS).

It's also in the build-up to a decision by option partner Mallinckrodt on its phase 3 MPC for chronic low back paindue in or before Septemberand a graft-versus-host disease (GVHD) candidate that should see pivotal results before year-end.

Read this article:
Mesoblast takes off as cell therapy for heart failure passes interim test - FierceBiotech

Read More...

Pioneering work on stem-cell therapies at UW deserves state support – Seattle Times

Sunday, April 9th, 2017

At the University of Washingtons Institute for Stem Cell and Regenerative Medicine, scientists and physicians are manipulating stem cells to heal and restore the function of hearts, eyes, kidneys and other tissues.

IF you have a heart attack, hopefully youll survive. But your body will be forever changed. The worlds best doctors cant undo the damage; instead, drugs and devices will help you live with a heart whose function too often dwindles.

The body cannot replace muscle cells that die in heart attacks maladies that help make heart failure the No. 1 global cause of death and our nations biggest health care expense. These patients face daily medication, decreased energy and, for the lucky 0.1 percent, the ability to qualify for an extraordinarily costly heart transplant and anti-rejection medication that also leaves them more vulnerable to other diseases.

Thanks to medical advances, heart failure has become a chronic condition that people are now managing for decades. The same is true for diabetes, kidney disease and arthritis. But with that longevity comes a tether to drug regimens whose costs rise seemingly at whim.

Dr. Charles Murry is interim director of UW Medicines Institute for Stem Cell and Regenerative Medicine.

These chronic diseases are a major reason that health-care costs hold center stage in Americans consciousness.

Amid our collective uncertainty, medical science offers one path of relief. Specifically, the engineering of human cells and tissues to restore vitality to poorly functioning organs.

The medical conditions named above share a common root not addressed by todays best care: The body is missing a population of cells that do critical work. If we could restore that population, we could cure many chronic diseases.

At the University of Washingtons Institute for Stem Cell and Regenerative Medicine (ISCRM), scientists and physicians are manipulating stem cells to heal and restore the function of hearts, eyes, kidneys and other tissues.

This year, we also seek a first-time investment from our state Legislature.

Weve pioneered techniques to grow unlimited human heart muscle cells in the lab. We were the first to transplant these cells into injured hearts and repair the injury with new tissue growth. UW Medicine will begin first-in-human tests of these cells in Seattle in 2019.

If this one and done treatment prevents heart failure in even the sickest 10 percent of heart-attack patients, our nation could save a staggering $3.5 billion per year in health-care costs. More importantly, these patients will lead longer, healthier, more productive lives.

Other ISCRM scientists are pursuing a gene therapy for muscular dystrophy, a devastating illness that often strikes young boys. The therapy, tested in Labrador puppies that were paraplegic as a result of the same, naturally occurring muscle-wasting disease, had the dogs leaping and frolicking in just weeks. A clinical trial is planned for 2018.

We are similarly probing therapies for cancer, kidney failure, diabetes and Alzheimers. And were doing this with the Northwests entrepreneurial spirit: In the past decade, ISCRM has patented 250+ discoveries with commercial potential and started 20 companies.

Legislatures in at least 11 other states, including California, New York, Wisconsin, Minnesota and Maryland, have invested cumulative billions in regenerative medicine. Most of that funding has gone to university-based research centers like ours.

To this point there has been no state investment in ISCRM. Nevertheless we have built a world-class program with federal grants and private philanthropy. But those dollars come in boom-and-bust cycles, and what we need now is stable funding to maintain competitiveness.

For this reason, the UW seeks $6 million in operating funds from the Legislature, starting with the next biennium, to recruit and retain top scientists, fund promising results at early stages, and train young researchers and clinicians.

We are grateful, at this juncture, that the state Senate included us in its initial budget.

We ask all legislators to invest in the health of our residents and in the promise of what weve accomplished so far. With stem-cell biology, we are ready to rebuild solid tissues like the heart and potentially cure our nations greatest cause of death and health-care expense.

Clinical success will make Washington a destination for heart repair and other regenerative therapies. This race is ours to lose.

Read more from the original source:
Pioneering work on stem-cell therapies at UW deserves state support - Seattle Times

Read More...

Sharon Berger loses fight against cancer – Jewish Chronicle

Sunday, April 9th, 2017

Jewish Chronicle
Sharon Berger loses fight against cancer
Jewish Chronicle
Sharon Berger, who launched a community-wide hunt for a bone marrow donor after being diagnosed with leukaemia, has died. She was 65. Her son Jonni announced her death on Twitter on Friday. He wrote: ... Her own personal challenge is to get through ...

Read the original:
Sharon Berger loses fight against cancer - Jewish Chronicle

Read More...

Scientists Say They’ve Identified a Gene Linked to Anorexia – Mental Floss

Saturday, April 8th, 2017

People withanorexia nervosahave a distorted body image and severely restrict their food to the point of emaciation and sometimes death. It's long been treated as a psychological disorder, but that approach has had limited results; the condition has one of the highest mortality rates among psychiatric conditions. But recently, neuroscience researchers at the UC San Diego School of Medicine who study the genetic underpinnings of psychiatric disorders have identified a possible gene that appears to contribute to the onset of the disease, giving scientists a new tool in the effort to understand the molecular and cellular mechanisms of the illness.

The study, published in Translational Psychiatry, was led by UC San Diego's Alysson Muotri, a professor at theSchool of Medicines departments of pediatrics and cellular and molecular medicine and associate co-director of the UCSD Stem Cell Program. His team took skin cells known as fibroblasts from seven young women with anorexia nervosa who were receiving treatment at UCSDs outpatient Eating Disorders Treatment and Research Center, as well as from four healthy young women (the study's controls). Then the team initiated the cells to become induced pluripotent stem cells (iPSCs).

The technique, which won researcher Shinya Yamanaka the Nobel Prize in 2012, takes any nonreproductive cell in the body and reprograms it by activating genes on those cells. You can push the cells back into the development stage by capturing the entire genome in a pluripotent stem cell state, similar to embryonic stem cells, Muotri tells mental_floss. Like natural stem cells, iPSCs have the unique ability to develop into many different types of cells.

Once the fibroblasts were induced into stem cells, the team differentiated the stem cells to become neurons. This is the most effective way to study the genetics of any disorder without doing an invasive brain biopsy, according to Muotri. Also, studying animal brains for this kind of disorder wouldnt have been as effective. At the genetic level as well as the neural network, our brains are very different from any other animal. We dont see chimpanzees, for example, with anorexia nervosa. These are human-specific disorders, he says.

Once the iPSCs had become neurons, they began to form neural networks and communicate with one another in the dish similar to the way neurons work inside the brain. Basically what we have is an avatar of the patients brain in the lab, Muotri says.

His team then used genetic analysis processes known as whole transcriptome pathway analysis to identify which genes were activated, and which might be associated with the anorexia nervosa disorder specifically.

They found unusual activity in the neurons from the patients with anorexia nervosa, helping them identify a gene known as TACR1, which uses a neurotransmitter pathway called the tachykinin pathway. The pathway has been associated with other psychiatric conditions such as anxiety disorders, but more pertinent to their study, says Mutori, is that tachykinin works on the communication between the brain and the gut, so it seems relevant for an eating disorderbut nobody has really explored that. Prior research on the tachykinin system has shown that it is responsible for the sensation of fat. So if there are misregulations in the fat system, it will inform your brain that your body has a lot of fat.

Indeed, they found that the AN-derived neurons had a greater number of tachykinin receptors on them than the healthy control neurons. This means they can receive more information from this neurotransmitter system than a normal neuron would, Muotri explains. We think this is at least partially one of the mechanisms that explains why [those with anorexia] have the wrong sensation that they have enough fat.

In addition, among the misregulated genes, connective tissue growth factor (CTGF), which is crucial for normal ovarian follicle development and ovulation, was decreased in the AN samples. They speculate that this result may explain why many female anorexia patients stop menstruating.

Muotrinext wants to understand what he calls the downstream effect of those neurons with too many TACR1 receptors. In other words, how does it affect the neurons at a molecular level, and what information do those neurons receive from the gut? This link between the brain and the gut is unclear, so we want to follow up on that, he says.

He also wants to look into thepotential to design a drug that could compensate for the large amount of TACR1 receptors, and the over-regulation of that receptor in the brainwhich would be a huge development for the notoriously difficult-to-treat disease.

While Muotri is excited about new avenues of research that can follow from this work, he doesn't see it as a panacea for the disease, but a way to begin to understand it more fully. He says, Its a good start, but arguably you have to understand what are the other environmental factors that contribute.

Read more:
Scientists Say They've Identified a Gene Linked to Anorexia - Mental Floss

Read More...

HT Exclusive: Mumbai docs save 3 ailing Bangladesh boys who pleaded for euthanasia – Hindustan Times

Friday, April 7th, 2017

Three Bangladeshi youngsters with a rare genetic disorder, which incapacitates muscles leading to early death, will quite literally walk out of hospital in a few months thanks to Mumbai doctors, Air India and the Union Ministry of External Affairs.

It all began in January, when Bangladesh resident Mohammad Tofazzel Hossen demanded his two sons Abdul, 24, and Rahinul,14, and his grandson Shohrab,7, be euthanised with permission from the government. The three boys suffer from Duchenne Muscular Dystrophy (DMD), a genetic disorder characterised by progressive muscle degeneration and weakness. The issue had broken into an international debate in January.

Caused owing to the absence of dystrophin, a protein that helps keep muscle cells intact, patients are likely to survive until the age of 25, said doctors from NeuroGen Brain and Spine Institute (NBSI), Navi Mumbai, which treated the three on a pro-bono basis.

After the international media highlighted Hossens desperate plea for euthanasia in January, Dhaka-based human rights organisation, Ain O Salish Kendra, started helping the family by connecting with experts across the world to seek options for medical treatment. By then, 55-year-old Hossen, who lives with his wife, two sons, daughter and grandchild in a one-bedroom house in the Meherpur district of Bangladesh, had sold his local shop and exhausted all the monetary options to avail treatment for youngsters.

I had lost all hope. Available medical facilities couldnt help my children; my life savings were no where close to meet the treatment needs for my sons, said Hossen.

Hossens fate changed overnight after doctors from NBSI, which specialises in stem cell therapy for rare neurological disorders, in collaboration with Meditourz, a medical tourism company, intervened to treat the patients free of cost. Doctors said till date, the hospital has treated more than 1,000 patients with similar disorders across 40 countries, with their first patient being a 31-year-old who is able to walk on his own.

Air India, on the hospitals request, agreed to fly the three patients and three attendants free of cost from Kolkata to Mumbai for treatment. The Indian Ministry of External Affairs made sure the requisite visa documentation for the three patients and their relatives to travel to India was approved on priority.

The family travelled by road to Netaji Subhas Chandra Bose International Airport, Kolkata, and arrived in Mumbai on April 2. Not only were the tickets arranged, but senior officers of Air India were present at both Kolkata and Mumbai airports to arrange hassle-free travel by arranging wheelchairs and other medical help.

The three youngsters, who were wheelchair-borne and had started to lose mobility of the limbs, underwent stem cell therapy on Tuesday. Doctors said within three to six months, all three of them will gain mobility and will be able to walk. The therapy restricts the disease progression and thus increases muscle capacity gradually, said Dr Alok Sharma, director of the medical facility, adding that the three patients will be discharged next week and will return for a follow-up next year.

They [doctors and Indian government machinery] are Gods gift to us. I will remain indebted to the Indian government all my life for saving my children, Hossen told HT. I was left with no option but to tell the doctors to euthanise my children. It is the most painful thing I have ever had to say, but it is only fair that if I am responsible for their ill-health, it is I who should set them free, he said.

India gave my sons and grandson a new life, something which our doctors or system failed to do, said Hossen.

Read

Bangladeshi father seeks mercy killing of sons, grandson

See the article here:
HT Exclusive: Mumbai docs save 3 ailing Bangladesh boys who pleaded for euthanasia - Hindustan Times

Read More...

Stem cells offer hope for autism – CNN

Wednesday, April 5th, 2017

It wasn't always so. Just a couple years ago, Ryleigh, 11, was scared of her sister when she'd throw tantrums and screaming fits.

"She would've fought and kicked," Ryleigh says, noting that it wouldn't have been possible to sit like this next to Gracie.

Gracie, 7, interrupts: "I don't even remember it."

"We do," says her mother, Gina Gregory.

Gracie has autism, a condition that affected nearly every aspect of her family's life after she was diagnosed at 2. But a new study is offering hope for the Gregorys and families like them.

The results were impressive: More than two-thirds of the children showed reported improvements. A larger second trial is underway, one its researchers hope will lead to long-term treatment for children with autism.

But for the Gregorys, the change in their daughter has been monumental.

Gone are the days of Gracie throwing fits in long lines at Disney World or during dinner at restaurants. When a tantrum intruded on family outings, her mom and dad wished they had T-shirts that said "My kid has autism" to ward off judgmental stares.

During autism therapy sessions, Gracie would kick, scream, spit and hit at her occupational therapist. "It was horrible to try to get her to sit there," her mother says.

Even just brushing her teeth or combing her hair could set her off.

Gracie, then 5, was on the mild to moderate autism scale, but her parents say the disorder consumed about 75% of their daily routine. After her participation in the study, that figure has been reduced to a mere 10%.

On a scale of 1 to 10, they rate her improvement around an 8 or 9; it's been that dramatic. She's even begun attending a "regular" school and thriving there, something her parents never thought possible. She'd been in various specialized school programs, and nothing was the proper fit.

Are Gracie's changes a result of the cord blood transfusion stimulating her brain? Or did her brain just mature as she got older? Could it be that her parents were subconsciously determined to magnify her improvements, given all their family had been through?

Those are questions the Gregorys still ask. But they do know that their daughter's transformation appeared to begin about six months after her transfusion in January 2015 and has continued ever since.

Her father's favorite adjustment is her newfound affection. Instead of shunning hugs, she now welcomes an embrace.

"We will say we don't think it's cured her. You still see some of the small idiosyncrasies that she does have," says her father, Wade Gregory. "But again, I think it's supercharged her learning curve. It's pushed her to do things she normally wouldn't do."

Her mother adds, "She got better, and we're just thankful for that -- whether it be the stem cells or not. We're just thankful for what changes have happened."

Each unit is designated by labels with specially designed adhesive to withstand extremely cold temperatures for decades. There are 14 cord blood freezers in all.

It is the cord blood in those freezers -- stored or donated by parents in case a serious illness develops -- that's at the cutting edge of this research.

About 30% never learn to speak, and many children even with early behavioral interventions still struggle to adapt. There also are no FDA-approved medications that improve the core symptoms of autism.

"I was very interested in collaborating with people here at Duke who could offer medical approaches that could enhance neuroplasticity, or the brain's ability to respond to treatment," Dawson says.

"We've been able to show that with some of these diseases, a cord transplant rescues them from death and also improves their neurologic outcome," she says.

She began wondering: Could cord blood help other children?

About a decade ago, her laboratory began clinical tests of children with cerebral palsy whose parents had banked their cord blood. Again, they saw positive results. And in some of those children who had autistic tendencies, they saw autistic symptoms improve. Another spark went off: What if they tested cord blood specifically for autism?

The safety trial began a little over a year and a half ago. Not only did it find cord blood to be safe, but 70% of the 25 children, age 2 to 6, had behavioral improvements as described by their parents and tracked by the Duke researchers. The research is largely funded by a $40 million donation from the Marcus Foundation, a nonprofit created by Home Depot co-founder Bernie Marcus.

The children traveled to Duke three times over the course of a year. They underwent a series of evaluations such as autism assessments, MRIs and EEGs to track their brain activity. On the first trip, the children received the cord blood infusion along with the intense evaluations. Each child received 1 billion to 2 billion cells, given through an IV in their arms or legs. At six months and then a year later, the children returned for more tests and observations.

"Some children, who were not speaking very much, had big increases in their vocabulary and their functional speech," Kurtzberg says. "Many children were able to attend to play and have meaningful communication in a way that they weren't before. Some children had less repetitive behaviors than they did when they came onto the study."

Adds Dawson, "The study was very encouraging. We did see positive results. However, it did not have a comparison group, which is very important in establishing whether a treatment is actually effective."

Both researchers can't stress that enough: that although they're cautiously optimistic about the results, they want the science to play out. They are now in the midst of the definitive trial on whether cord blood can treat autism -- a double-blind, placebo-controlled trial involving 165 autistic children, ranging in age from 2 to 8. The FDA has oversight of the study.

During the phase II study, the children on their first visit receive a cord blood infusion -- either their own or from a donor -- or they get a placebo. They also undergo a battery of assessment tests and brain monitoring.

On their second visit six months later, the children receive a second infusion with whatever preparation they did not receive the first time and undergo more evaluations. The order of the infusions is not known. Researchers will monitor them for the next year for any sign of behavioral improvements.

It's known as a crossover trial, in which each subject gets the treatment and the placebo but in a different order. Researchers say it would have been nearly impossible to find participants if parents knew that their children might not receive an infusion.

How groundbreaking would it be if the trial shows similar results to the safety study?

"If we can show that receiving an infusion of cord blood is more effective for improving social behavior than the placebo," Dawson says, "then this will be game-changing."

Kurtzberg adds, "We'll be extraordinarily encouraged if the second trial shows that the cells benefit children when the placebo does not. We will consider that a breakthrough."

Both researchers were shaped early in life by the struggles families face raising autistic children. As a teen, Dawson babysat twins with autism who lived across the street. "It was just an inspiration to devote my career to improving the lives of people with autism," she says.

Kurtzberg was similarly affected. When she was a junior in college, she would visit a girl with severe autism and play with her as a means of behavioral intervention. "The family still writes to me," she says.

It is for this reason -- their longtime devotion to families raising children with autism -- that both issue a heap of caution. Although they're excited about the results of the first study, Kurtzberg says, "we don't want to mislead people and claim it's working before we have definitive proof."

Adds Dawson, "It's important for parents who might hear about cord blood as a potential treatment for autism to know that we are working very hard to know the answer to that question. We aren't there yet."

Kurtzberg has a hypothesis about what may be happening: that certain immune cells within the cord blood are crossing the blood-brain barrier and altering brain connectivity while also suppressing inflammation, which may exist with autism.

"I feel more confident now because of our (cerebral palsy) study, which preceded this study and does show benefits," Kurtzberg says.

"One has to be very careful when interpreting results that haven't come from properly controlled, double-blind studies," he said. "All I can say is that it would be wonderful if this treatment was effective, but one has to be very cautious before reaching any conclusions."

Even without a placebo effect, he says, many factors could have resulted in an improved outcome in the first study: The growing children could have acquired skills simply through maturation, possibly enhanced by occupational therapy, and their parents may have clung to positive gains, creating a biased outcome.

Kriegstein of UCSF also wonders whether cord blood is really stimulating cells in the brain and creating new connections. "There are so many unanswered questions about what might be going on here, it becomes very difficult to evaluate the proposed mechanism," he said.

"The question remains: How do these cells injected intravenously wind up in the brain, how do they target the appropriate brain regions, and what are they doing that could improve brain function?"

An 8-year-old boy with autism sits at a table in a room within Duke's Center for Autism and Brain Development. Clinical research specialist Michelle Green watches from behind a two-way mirror. Two cameras in the room feed computer monitors, allowing her to further analyze his behavior.

Dr. Lauren Franz, a clinician, works with the boy in the room.

"What kind of things make you feel threatened or anxious?" she asks.

"Like when I'm done with a test," the boy says.

"How does it feel when you're frightened or anxious? How does that feel?"

"Like pretty weird," he says.

The boy is participating in the second trial, and he's returned for his six-month assessment and second infusion. Researchers don't know which infusion he received first: the cord blood or the placebo.

But they track, record and monitor the slightest of details. Although it might seem like an innocuous conversation, researchers will compare the results with those of his first visit and any follow-ups. Was he able to sit still at the table before? Could he articulate his thoughts? Did he talk before the study? Has he improved?

At the Gregorys' home in Florida, Gracie's parents remember when she went through those same tests. The best investment they ever made, they say, was the $2,000 spent on banking her cord blood. At the time, it was just a precaution; her autism diagnosis didn't come until three months after her second birthday.

They know the desperation of families raising a child with autism -- of longing for their daughter to have a shot of normalcy in life. "You can't quantify it. You can't measure it. You want to see your child succeed," her father says.

Mom and Dad recently watched old home videos, of Gracie singing inaudibly, of her covering her ears when "Happy Birthday" was sung for her third birthday, of showing no emotion on Christmas when she was 2. "I forgot how bad it was," her mother says.

They hope the current study leads to similar successes -- and results in breakthrough treatment for autistic children everywhere.

Read the original:
Stem cells offer hope for autism - CNN

Read More...

Chemical Weapons in Syria Overburden Already-tattered Medical Infrastructure – Laboratory Equipment

Wednesday, April 5th, 2017

A chemical weapon attack in Syria on Tuesday killed some 70 people, including sleeping children, according to multiple eyewitness accounts. Hundreds more were sickened.

But the latest use of the weapons of mass destruction, illegally banned internationally, has highlighted the difficulty in treating victims of such attacks.

The nerve agents used in Tuesdays airstrike in the rural province of Idleb were from the family of organophosphorus chemicals, according to the World Health Organization. Some sources indicate it may be sarin gas.

The WHO immediately dispatched shipments of Atropine, a belladonna alkaloid administered to acute poisonings like that of sarin gas, as well as steroids to treat the symptoms among the children and civilians who were affected.

But area hospitals were also damaged and couldnt accept all the wounded, according to the WHO. Al Rahma Hospital was damaged this week, and temporarily nonfunctional and the Maara Hospital was extensively damaged by ordnance on Sunday. Accordingly, many of the patients have been shipped to facilities in southern Turkey.

More drugs are on their way from WHO storage locations in Turkey, WHO added.

The WHO had stores of Atropine on hand near the scene in Idleb. The preparations were a result of a series of attacks since the first chemical weapons usage in 2012. New protocols, protective equipment and even lessons to Syrian civilians have attempted to limit casualties. Last year, the WHO trained 200 clinicians on emergency triage for chemical exposure, and an additional 65 doctors were trained in northern Syria. Most of those doctors were from Idleb.

Previous attacks have featured chlorine gas. But this attack is believed to have employed sarin, according to experts with Amnesty International.

The White House and the United Kingdom have both condemned the attack as an offensive by the Assad Regime, which has previously employed chemical weapons against various rebel factions in the civil war, which has raged since 2011.

Amnesty International described the usage as an air-based chemical attack that is a war crime. They called on the United Nations to do something about it.

Security Council members, and in particular Russia and China, have displayed callous disregard for human life in Syria by repeatedly failing to pass resolutions that would allow for punitive measures to be taken against those committing war crimes and other serious violations in Syria, said Anna Neistat, senior director of research at Amnesty International.

Russian officials and Assad supporters have contended that a conventional strike on a rebel stockpile of chemical weapons is what caused the casualties. Most agencies have rejected that explanation.

The attack occurred in Khan Sheikhoun, a small town on the Damascus Highway, and one of the few remaining opposition holdouts in northeastern Syria. A nurse at the Al Rahma hospital told Amnesty International he was having his morning coffee at 6:20 a.m., when he and other staff members heard far-off thumps. Just 15 minutes later, the gruesome parade of victims started arriving.

The smell reached us here in in the center; it smelled like rotten food, the nurse said. Weve received victims of chlorine attacks before this was completely different. Victims had vomit from the nose and mouth, a dark yellow color, sometimes turning to brown. Paralysis in respiratory functions children were dying faster than adults because of this. We tried injections but it just didnt work. Victims were unable to swallow, they were unconscious, completely unresponsive.

Recent studies have indicated that emergency interventions for chemical attacks are lacking in modern medicine. A study in the journal Chemico-Biological Interactions published in 2014 found that therapeutic options are limited as victims essentially choke to death on sarin or other agents but stem cells may be a treatment option of the future.

See the rest here:
Chemical Weapons in Syria Overburden Already-tattered Medical Infrastructure - Laboratory Equipment

Read More...

Hunt for cancer ‘tipping point’ heats up – Nature.com

Tuesday, April 4th, 2017

Garo/Phanie/Science Photo Library

Biopsies can help track when a benign tumour turns malignant.

Databases worldwide are rapidly swelling with the sequences of thousands of cancer genomes. Now, some scientists are advocating that researchers shift their focus back in time: to study the DNA of tumours in their adolescence, before they commit to being cancerous.

At the American Association for Cancer Research (AACR) annual meeting in Washington DC, researchers gathered on 2 April to discuss the growing call to sequence the genomes of pre-cancerous lesions abnormal growths that sometimes progress into full-blown cancers. The results could help researchers to determine which tumours warrant treatment and could aid the development of therapies to block cancers on the path to malignancy.

It is a project that is now near the top of the cancer research wish list, says oncologist Elizabeth Jaffee of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, Maryland. This is something that has really taken off throughout the cancer community, she says.

The idea could be one of the next 'big science' projects for cancer. The idea is to borrow some tactics such as coordination among scientists and sequencing centres from The Cancer Genome Atlas, one of the first and biggest cancer genome efforts, which characterized the genomes of 33 cancers using samples from more than 11,000 people.

But the new 'Pre-Cancer' Genome Atlas would also study cancers over time. It would ideally include multiple snapshots of the same tumour as it developed, in the hope that researchers will be able to determine what changes pushed it across a tipping point to become cancerous.

Individual laboratories have already embraced this concept. Pulmonologist Avrum Spira of Boston University in Massachusetts has been studying the origins of lung cancer by sequencing samples from people with pre-cancerous lesions in their airways. Such biopsy samples are typically taken every 6 or 12 months.

Lung cancer, he says, seemed a logical testing ground for the sequence-over-time approach. It is the most common cause of cancer death worldwide. The major reason: we almost always detect it late, he says, adding that as his team carried out the sequencing, it hit us that this could be a paradigm that applies to other cancer types.

Thomas Kensler, who studies cancer prevention at the University of Pittsburgh in Pennsylvania, points to recent advances in characterizing thyroid cancer that have led to genetic tests to distinguish which tumours warrant treatment. Not every lump in the thyroid is necessarily destined to be a cancer, he says.

At the AACR meeting, cancer researcher and physician Rafael Bejar of the University of California in San Diego presented his ideas for extending the model to include liquid tumours such as leukaemias. Normal blood is derived from many stem cells, and genetic sequencing can match blood cells to the stem cells from which they were derived. So if a blood test reveals that one lineage of stem cells is beginning to take over the population, it could be an early sign of cancer and subsequent monitoring could reveal if the disease takes hold.

But a coordinated effort, says Bejar, could boost the impact of these individual projects. Last September, advisers to the US Cancer Moonshot initiative an effort to double the pace of cancer research in five years included a pre-cancer genome project among the schemes they recommended for investment. And Spira says that the project was discussed at a US National Cancer Institute meeting in late March, and will be taken up again at a meeting in June.

What the community wants next, say advocates of the programme, is a firm financial commitment to take the project from concept to reality. Theres a lot of enthusiasm, Bejar says. People are moving forward.

Link:
Hunt for cancer 'tipping point' heats up - Nature.com

Read More...

How new mums’ umbilical cord blood can save lives as ‘collectors’ use it for stem cell transplants – Mirror.co.uk

Tuesday, April 4th, 2017

Anyone who has watched Channel 4s hit series One Born Every Minute will tell you that seeing new life come into the world can be pretty magical.

Carolyn Sayle and her daughters Neenah and Shauni Higgins can wholeheartedly attest to that.

Although they have been present at countless births , they are not midwives. They have an altogether different role but one that could potentially save someones life.

All three work for the charity Anthony Nolan as dedicated cord blood collectors.

Their job involves asking expectant mums to donate their umbilical cord blood which would usually be thrown away for use in stem cell transplants.

Such transplants are often used when a patient doesnt have a match from an adult donor, such as if the patient is from an ethnic minority background, because the young cells are more adaptable to different genetic types.

Shauni says: Donating cord blood can make the difference between life and death for somebody who is suffering from blood cancer or leukaemia and its risk-free for the mother and baby .

Carolyn, 55, was the first to start working for the charity in March 2014 after relocating from Manchester, where she was an IVF coordinator, to Saxmundham, Suffolk, to live with her partner Paul, 60.

She says: Id known about Anthony Nolan for years, having joined the register as a bone marrow donor during one of its first big recruitment drives in the 70s.

Its a really important job that we do, and it still fascinates me that something we would otherwise throw away could save someones life.

Carolyn, who is based at Kings College Hospital in London, says collection is the easiest part of the job. So far she has done 455.

Its the bit that comes before thats difficult, she says. The majority of expectant mothers dont even know they can donate their placentas and umbilical cord.

Most are already in labour so theyre not in the best frame of mind when we approach them. Youve got to have people skills and know when not to go in the look on their face will tell you.

Carolyn says she starts every shift never knowing what will happen.

Weve got ladies walking in constantly in all stages of labour, she says. We try to speak to them as they come in as well as keeping track of deliveries.

"It can be a bit hectic when youve got a few ladies pushing and you dont know which one youll collect from first.

Once a woman has consented, a cord collector will be there in the delivery room or in theatre if they are having a caesarean section.

After delivery, the cord and placenta are taken into a separate room. The collector has to massage the placenta and the blood drains through the cord into a collection bag before it is cryogenically frozen.

One of Carolyns cord collections was used in a transplant last year. She recalls: I thought, How fantastic is that? I was so proud and told Neenah and Shauni straight away.

Video Unavailable

Click to play Tap to play

Play now

Watch this video again

Video will play in

Staff arent told where a donation is issued in order to maintain confidentiality, but Anthony Nolan can track how patients are doing further down the line.

Carolyn says: Its early days with it only being last year so I havent heard anything yet.

Shauni, 23, was so impressed with her mums work she became a cord collector herself at St Marys Hospital, Manchester, last May.

Shauni, who lives in Bagley, Manchester, with partner Jordan, 28, explains: Id loved the few placements Id done working in hospitals, and quickly realised I found my dream job when I joined Anthony Nolan.

On my first day I went into theatre to see a c-section. It was amazing and the first time Ive ever seen a birth. Nothing prepares you.

She says one of the most difficult parts of the job is when women decide not to donate. It seems such a shame for something so valuable to go to waste, she says.

Nearly all the cords we collect get used for something those that arent clinical-grade are used in research.

Mum-of-one Neenah, 28, started working alongside her sister as a cord collector at St Marys last July after deciding on a career change after working as an Estee Lauder manager and make-up artist.

She donated her own cord blood when she gave birth to Penelope, 20 months, and says: Id heard so much about donating from mum and I wanted to give something back. I wanted to do something that helped people.

Neenah, who lives in Urmston, Greater Manchester, with fianc Ian, 30, now wears scrubs and no make-up to work. She says: A lot of the time I get blood on my face so I dont want to be worrying about smudging my foundation when I wipe it off.

But being on a maternity unit can be an emotional roller coaster.

She says: I had a lady who had been induced but she had a placentalabruption and was rushed into theatre for an emergency c-section. She lost a lot of blood so I couldnt do the collection and the baby was very poorly.

That was horrible. It does affect you because you build up a relationship with people. You can sometimes come home after a shift and have a cry.

Working together has brought about a bit of family rivalry.

Neenah says: Last week Shauni was saying shed extracted 235ml of blood and I said, Well, I got 240ml.

Shauni adds: We have a bit of a competition when it comes to the size of the collections. She beat me by five. I always beat mum though!

Donating cord blood is completely risk-free for mother and baby, and doesnt interfere with your birth plan.

Anthony Nolan can currently collect cord blood in four hospitals St Marys, Manchester; Kings College Hospital, London; Leicester Royal Infirmary and Leicester General Hospital.

You can only donate if youre giving birth at one of these hospitals and you cannot donate if you are having a home birth.

You can register your interest online before birth at anthonynolan.org .

Each mum who donates is given a baby bundle, which includes a certificate and babygro, as a thank you.

There is no subsequent contact between cord donors and recipients who then benefit.

The NHS cord blood bank collects in a further six hospitals Barnet General Hospital, Luton and Dunstable Hospital, Watford General Hospital, and Londons Northwick Park, St Georges and University College Hospitals.

Read the original here:
How new mums' umbilical cord blood can save lives as 'collectors' use it for stem cell transplants - Mirror.co.uk

Read More...

Willson: Hippocrates would have supported euthanasia – Rocky Mountain Collegian

Tuesday, April 4th, 2017

Editors Note: All opinion section content reflects the views of the individual author only and does not represent a stance taken by the Collegian or its editorial board.

Alongside embryonic stem cells and abortion, the practice of physician-assisted death is one of todays most contested bioethical issues. Those opposed to aid in dying argue that the practice is out of line with fundamental medical principles, mainly those based upon the oft-quoted Hippocratic Oath. Such a claim, however, is erroneous as modern-day Hippocratic Oaths are not identical iterations of the ancient Greek declaration. I would actually go so far as to argue that physician-assisted death is supported by contemporary physicians pledges. With this in mind, I believe we should view Death with Dignity not as an issue at all, but rather as a new, necessary form of treatment that has grown out of a rapidly evolving medical landscape.

Physician-assisted death (PAD) refers to a patients conscious decision to end their life by way of lethal substances using the direct or indirect involvement of a physician. A situation where this practice might be employed is in the case of terminal cancer. If the affected patient knows they are going to die within X number of months and does not wish to undergo painful chemotherapy and/or palliative treatments until then, they can hasten death with the help of a licensed physician.

Few statesonly six plus the District of Columbiahave legislation permitting physician-aided death. This is in large part due to persistent qualms about the supposedly immoral nature of helping someone die. A large part of these beliefs are influenced by religious dogma, especially in the Catholic Church, as well as pro-life political movements. But, particularly in the medical field, some argue that helping a patient reach lifes end diametrically opposes the primary tenets of the Hippocratic Oath: primum non nocere, or, first, do no harm.

There are twothings wrong with this argument.

First, the above mentioned phrase is not actually from Hippocrates eponymous oath but is believed to have come from his work, Of the Epidemics. Granted, there is similar language found in the actual Hippocratic Oath: I will use treatment to help the sick . . . but never with a view to injury and wrong-doing. The only reason I point out this discrepancy is to show that the argument of primum non nocereis not technically a part of the physicians pledge and thus should not be a major argument for anti-PAD oath-takers.

Secondly, many modern medical schools have their own versions of the Hippocratic Oath, drawing elements from the original text, while some do not require them at all. Thats not to say that some schools are more ethical than others, just that certain institutions view the practice of medicine in different waysas they should, for the field is subject to change as major advancements or discoveries are made.

The genuine Hippocratic Oath, written circa 400 BCE, stresses admirable values, such as treating patients with the best of ones skills, handing down medical knowledge to subsequent generations, and ensuring patient consent to treatment. But, some elements of the oath, such as those pertaining to religion or those forbidding abortions, fell by the wayside over the years. Some parts of the oath were adopted into modern versions, while others were omitted. These variations show not only a growing individualism in perception of medical practice, but epitomize the complexity and subjective nature of bioethics.

Interestingly, only 14 percent of modern day Hippocratic Oaths forbid euthanasia.If a doctor argues that they cannot perform PAD due to its conflict with a sworn pledge, it is statistically unlikely that their oath actually forbade the practice.

Even when discounting the semantics of Hippocratic Oaths, I firmly believe that we are the captains of our souls as well as our own bodies. If diagnosed with a terminal illness and given the option of: a) undergoing painful treatment until natural death, or b) ending things quickly in a relatively painless way, I am positive I would choose the latter. Wouldnt you?

But, dont just take my word for it. Six states and the District of Columbia have already legalized PAD, and it can be expected that number will increase in coming years. The growing level of acceptance can be seen on both ends of the patient-provider spectrum.

Patients have a number of reasons for supporting euthanasia: alleviation of negative side effects; regaining a sense of control over an otherwise ungovernable illness; and eliminating fears of the future, such as worsening quality of life and/or becoming a burden on loved ones.

Physicians too are able to see why support of PAD should be given. As medical practitioners, physicians aim to show every patient care and compassion, while also providing their best advice for course of treatment. To discount the compassionate nature of euthanasiaits literally giving a patient asked-for relief from painis to discount the shared message of all Hippocratic Oaths: to avoid wrongdoing towards the patient. If a sick person is suffering and a doctor has the ability to end that pain, why wouldnt they?

We shouldnt argue that PAD is wrong because it violates the Hippocratic Oath. Instead, we should debate why this practice is still inaccessible to so many who are suffering. Unfortunately, Im out of paper space, so thatll have to be a discussion for another day.

Note: I have chosen not to use the familiar term physician-assisted suicide due to its perpetuation of prejudice and negative sentiments towards individuals who choose to die with dignity.

Lauren Willson can be reached at letters@collegian and online at @LaurenKealani

Read the original:
Willson: Hippocrates would have supported euthanasia - Rocky Mountain Collegian

Read More...

Stranger gives Fairfield Twp. man another chance at life – Hamilton Journal News

Monday, April 3rd, 2017

FAIRFIELD TWP.

Eleven years ago, Tyrel Jensen, then a junior at Taylorsville High School in West Valley City, Utah, was inspired by Michael Brecker, a professional saxophone player who was battling leukemia and needed a bone marrow transplant.

While researching the disease, Jensen learned about a donor registry, http://www.bethematch.org. He registered, swabbed his mouth and returned the results in a sealed envelope. Brecker died in 2007, and Jensen said he forgot about registering.

At the same time 1,652 miles away in Fairfield Twp. Chris Allen was fighting for his life. His body was filled with Stage 4 lymphoma, and even though he had defeated the disease twice before, the latest diagnosis was dire: Either get a stem cell transplant or die in three months.

We thought we had it, but it has come back with vengeance, Allens doctor told him. Its not looking good. This is going to be a whole new game this time. Were going to take you the closest to death you will ever be.

Allen responded: I dont want to go through this again. Im out. I dont want to do it.

But you are going to die, his doctor said.

Initially, Allen decided he was tired of fighting and was prepared to die. But his family and friends convinced him he was being selfish, and he needed to take every step possible to save his life.

Allens two older brothers were tested as possible stem cell donors, and while one was a match, Allen didnt feel his brother was healthy enough for the procedure.

Then he received the call that changed his life forever and connected two families the Jensens and the Allens.

We got a match, Allen was told by the transplant coordinator.

Just four simple words. Four life-saving words.

Allen was told nothing about the donor.

Jensen had his blood drawn on June 14, 2015, and the bag was flown from Utah to Cincinnati. As Allen was waiting for the procedure to begin, he was handed the bag that was tagged, A, RBC Compatible, Plasma Compatible.

At the time Allen told the eight people in his hospital room: Im holding my life right here.

Not a religious man, Allen admitted he asked a friend to place his hands on the bag and pray for a positive outcome.

I might need a little help here, Allen told those in the room.

The stem cell transplant procedure lasted 45 minutes and was performed on June 15, 2015, forever known as Allens second birthday.

Allen, 57, remained in the hospital for one month where his progress was constantly monitored. After his test results showed his body was accepting the transplant, he was released, but still he had to remain indoors because of the possibility of infection.

Last summer, one year after the transplant, Allen was called and informed about his donor, a young man with a wife and a son in Utah. Before the transplant, the men were strangers. That changed on June 15, 2015.

Blood brothers now, Allen said.

When he got up the nerve, he called Jensen, 27, unsure what to say. What do you say to someone who just saved your life? Thanks seems a little insignificant.

To celebrate the transplant, Allen invited Jensen, an account manager at a software company, and his family to attend their annual summer party in their back yard. Jensen came by himself, spent three days with the Allens and was an instant celebrity at the party. Allen and his longtime girlfriend, Teresa Spurlock, stood on the stage and announced to the crowd there was one special person in attendance.

The young man that saved my life was introduced, Allen said.

The party was surreal, Jensen said. It was kind of a dream in a way. It was a lot of people I dont know but somehow feel so closely connected to.

Allen now is a living billboard for the importance of being a donor.

Without a donor, he said, Id be dead by now.

As a phone conversation ended Friday morning between the two men, Allen was still thanking Jensen.

Thanks again, he said. I will never be able to tell you how much I love you. Thanks again, pal.

For Jensen, being a donor brought the transplant full circle. He has a brother who also received a transplant that gave him a few more years, Jensen said.

I knew what it was like to receive after going through it with my brother, he said.

Jensen said it made him feel pretty emotional to help Allen.

There was a pause on the phone.

Grateful, he said, his voice cracking. And its one of those things where my contribution really was so much smaller than the effect it had on him. It was a small sacrifice from my perspective. I feel like I gave so little. You dont have to give much, but the difference it makes is huge.

The difference between life and death.

Read more from the original source:
Stranger gives Fairfield Twp. man another chance at life - Hamilton Journal News

Read More...

Promising Drugs in Clinical Development To Treat Advanced Colorectal Cancer – P&T Community

Saturday, April 1st, 2017
Promising Drugs in Clinical Development To Treat Advanced Colorectal Cancer
P&T Community
Excluding skin cancers, colorectal cancer (CRC) is the third most common cancer diagnosed in men and women in the United States. Overall, the lifetime risk of developing the disease is approximately one in 21 (4.7%) for men and one in 23 (4.4%) for ...

Read more:
Promising Drugs in Clinical Development To Treat Advanced Colorectal Cancer - P&T Community

Read More...

If Young Blood Can Combat Aging, It May Be Thanks to Just One Protein – Futurism

Saturday, April 1st, 2017

In Brief Studies are being done on the value of replacing older blood with younger blood via transfusions. Other researchers are studying the effects of a certain protein, osteopontin, on blood cell production. 1000 Ways To Live Forever

Society is gradually changing its classification of aging as a natural phenomenon to a disease. We have made strides in our research on preventing and potentially reversing the effects of aging.In addition to the ongoing research in molecular biology ontelomeres, there is the interesting idea of utilizing young blood to combat aging. Ironically, the legends of Dracula might be vindicated in light of new research involving young blood to rehabilitate cognitive abilities in mice, which has inspiredclinical trials that may give patients a chance at beating the Grim Reaper.

Ambrosia, a company inspired by the work done by Stanford University neuroscientistTony Wyss-Coray with parabiosis in mice, charges $8,000 per patient for its human clinical trial ofparabiosis. Although there may be 600 people whotake part in the study transfusing 1.5 liters of plasma with donors between the ages of 16 and 25, thestudy is being done without the blessing of Wyss. He believes that the study does not genuinely represent the science and that, theres just no clinical evidence, and youre basically abusing peoples trust and the public excitement around this.

While Ambrosia is operatingwithout clinical evidence to support the trials, the science behind utilizing young blood in repairing and restoring aged cellular processes is worth taking a look at.

Red and white blood cells are produced from stem cellswithin bone marrow, and as we grow older, our bodys ability to replenish the number of red and white blood cells greatly depletes. Similar to the mouse trials ran by Wyss-Coray, researcherHartmut Geigerand his team at the University of Ulm in Germany looked at the bone marrow in mice at varying ages and determined that older rodents produce very low levels of the protein osteopontin.

Rather than looking at blood transfusions for apossible solution like Wyss-Corays team, Geigers team looked the potential of stem cells to test the importance of the deficient protein.The team introduced fresh stem cells into mice that had little to no osteopontin and noticed that the stem cells aged very quickly. When older stem cells were introduced to a dish with osteopontin and anactivator protein, the stem cells began to propagate blood cells.

While companies like Ambrosia are testing blood transfusions on humans to mimic an experiment that utilized a shared circulatory system between an older mouse and a younger mouse, Geigers team notes that long-term studies must be done on their work to verify the effect of osteopontin on rejuvenating cells completely.

The team is developing a drug with the protein and its activating factor, but they do not promise a fountain of youth. They do believe that there would be benefits for the immune systems of the elderly, which may be better positioned to fight diseases that are linked with cardiovascular agingafter takingthe drug.

While all this talk about immortality is exciting, it might be a while before we can actually reap the benefits of researchers studiesin the way we hope. In the meantime, we can keep dreaming away death.

See more here:
If Young Blood Can Combat Aging, It May Be Thanks to Just One Protein - Futurism

Read More...

‘Killing Leuk:’ Kelly Marre’s book signing April 8 – Mat-Su Valley Frontiersman

Saturday, April 1st, 2017

WASILLA I always say my story begins with Logan, Kelly Marre says.

Her first born son, Logan passed away at the age of 11 in 1998 after fighting acute lymphoblastic leukemia (ALL). Nineteen years later, Marre carries his memory everywhere. As an active member in the volunteer community, particularly focusing her efforts on Leukemia and bone marrow registries, Marre states she tries to do everything with purpose.

When God took Logan, it did not compromise my faith. I could have been bitter and cursed his name from a mountaintop. But I didnt. Look around everything is beautiful. Logans story almost 19 years after his death lives on (Sharing her story and her sons) It brings people hope and that is my purpose, Marre says.

Kelly, too, is battling leukemia. Now 22 months into remission, Marre has survived thus far and has a story to share.

Saturday, April 8, from 11am to 2pm is Kelly Marres book signing event. Titled, Killing Leuk, the book chronicles her journey through the stages of Acute myeloid leukemia (AML).

The book-singing event will be inside the new Little Millers Caf off the Palmer-Wasilla Highway. Guests can stroll into the cozy lounge and casually waft through the afternoon with Marre as she sells and signs books and welcomes meaningful conversations. She invites anyone who wants talk about overcoming the challenges of pain and suffering, hoping to a brighter future.

Marres goal is to donate $1 for every book sold. If they all sell that would mean 4,000 books to raise $4,000 to donate to her charities of choice: The Ronald McDonald Foundation, Be the Match (bone marrow registry), the Make-a-Wish Foundation, and the Leukemia & Lymphoma Society.

Nineteen years after her son Logans death, Marres book details her dealings with loss, illness, high hopes and setbacks, hope, strength, and ultimately inspiration; how she kept fighting through every strained step, every clump of hair fallen, each relapse. All with the love and support through faith, friends, family, and the heartbeat of the community.

Logan was pretty famous in our community, Marre said.

If you look back in the Frontiersman archives, you will find stories surrounding Marres family and the impact it had on the community; a living, breathing story arc of love and loss, whirling a dramatic wind of positive momentum, all around.

You know what, we all have stories; we all have circumstances, and we all have pain and weve all had suffering, she said. Its what we do with that its our journey. We were given a journey and its all how we walk that journey that can make our break us.

Both Logan and Kelly were unable to find matches for bone marrow transplants. Both, however, received cord blood units from donated umbilical cords.

The umbilical cord is rich, rich in stem cells. Unfortunately in Alaska we dont have that opportunity and Im trying to change that, Marre said. Thats why I get involved with the be the match bone marrow registry drive. We need to find matches for everybody.

Anyone interested in visiting Kelly Marre is welcome to do stop by this Saturday. It appears Marre and her sons stories have already given people hope. Theres always room for more.

Read the original:
'Killing Leuk:' Kelly Marre's book signing April 8 - Mat-Su Valley Frontiersman

Read More...

Company Spotlight: Cellect Biotechnology – RTT News

Friday, March 31st, 2017

Shares of Cellect Biotechnology Ltd. (APOP) are up more than 44% over the last 5 trading days.

With its shares currently traded on both the NASDAQ and Tel Aviv Stock Exchange, Cellect is the company behind ApoGraft, a breakthrough technology for the isolation of stem cells from any given tissue.

Cellect's ApoGraft technology is aiming to turn stem cell transplants into a simple, safe and cost effective process, reducing the associated severe side effects, such as rejection and many other risks, such as Graft versus Host Disease.

Graft versus Host Disease, a condition in which the transplanted immune cells attack the recipient's cells, is a common complication associated with *allogeneic stem cell transplantation. (*Allogeneic stem cell transplantation involves transferring the stem cells to the recipient from a genetically matched relative or other donor).

The positive results from a clinical trial of ApoGraft that involved 104 healthy donors of blood stem cells reported in February of this year demonstrated that Cellect's ApoGraft is a safe, robust and reproducible process for clinical use.

According to the company, the use of the ApoGraft to process human stem cells for bone marrow transplantation resulted in a significant increase in the death of mature immune cells, primarily T Lymphocytes, without compromising the quantity and quality of stem cells. The process takes only a few hours as compared to days of complex and expansive lab work with traditional methods, is anticipated to be extremely cost effective in comparison to current approaches, and has the potential to significantly reduce the risk of GvHD.

The first blood cancer patient was treated in a phase I/II trial of ApoGraft in February of this year, and on March 27th, the company announced that the first stem cell transplant procedure has been successfully performed.

With the first stem cell transplant procedure being successful, Cellect has received the go-ahead from the independent Data and Safety Monitoring Board for enrolling additional 2 cancer patients for ApoGraft transplantation treatments.

The study is designed to enroll 12 patients.

Key Financials:

- Net loss for the fourth quarter ended December 31, 2016 was $0.75 million or $0.007 per share compared to a net loss of $0.96 million or $0.012 per share in Q4, 2015.

- Cash totaled $8.0 million at December 31, 2016 compared to $3.1 million on December 31, 2015.

- The number of shares outstanding is 107.58 million (Data sourced from Yahoo Finance).

In order to maximize the value of the Company for all stakeholders, Cellect plans to delist from the Tel Aviv Stock Exchange (TASE) in accordance with section 350 to the Israeli Company Law.

Shares of Cellect Biotechnology touched an all-time intra-day high of $13.50 on Mar.27, 2017 on the NASDAQ. The stock closed yesterday's trading at $8.98, up 2.75%.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

View original post here:
Company Spotlight: Cellect Biotechnology - RTT News

Read More...

Page 25«..1020..24252627..3040..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick